Genetic Analysis AS (GEAN): Mandatory notification of trade – Primary Insiders
OSLO, NORWAY - 13 January 2022: Genetic Analysis AS (“GA” or “the Company”) announce that members of the management have bought GEAN-shares.
Ronny Hermansen, CEO in Genetic Analysis AS, has through the fully owned company InVitroDia AS today bought 14,488 GEAN-shares at an average price of 6,90 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 169.040 shares and 49,998 subscription rights.
Eilert Aamodt, CFO in Genetic Analysis AS, has through the fully owned company E. B. Aamodt AS today bought 10,000 GEAN-shares at a price of 6,46 NOK per share. The shares were acquired on the Spotlight Stock Market. Eilert Aamodt including controlled company owns 48,460 shares and 49,998 subscription rights following the transaction.
For further information, please contact:
Ronny Hermansen, Chief Executive Officer
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com